Related by context. All words. (Click for frequent words.) 75 Complete Response Letter 75 FDA Approvable Letter 72 approvable letter 71 Complete Response letter 71 FDA approvable letter 71 Complete Response 67 FDA Complete Response 65 Complete Response Letter CRL 64 Marketing Authorization Application 64 approvable letters 63 Fast Track Status 62 PDUFA Date 62 Approvable letter 61 Marketing Authorisation Application 61 orphan designation 61 Intermezzo ® NDA 61 Warning Letter 60 ZEGERID Chewable Tablets 60 Orphan Status 60 Fast Track Designation 60 NDA resubmission 60 Biologics License Application 60 Priority Review 59 sBLA 59 Marketing Authorization Application MAA 59 BLA submission 59 Surfaxin lucinactant 59 Resubmission 59 Fast Track designations 59 Supplemental Biologics License Application 59 APF# NDA 59 PROVENGE sipuleucel T 58 IND submission 58 Approvable 58 BLA filing 58 Investigational Device Exemption 58 Staff Determination Letter 58 SURFAXIN 58 lorcaserin NDA 58 Surfaxin 58 Fast Track designation 58 Act PDUFA date 58 Citizen Petition 58 indiplon capsules 58 IND Investigational New 58 Orathecin 58 Impax ANDA 58 FDA Orphan Drug 58 Pre IND 58 IND Filing 58 NDA Submission 57 sNDA 57 Orphan Drug designation 57 GRAS notification 57 PDUFA date 57 Orphan Drug Designation 57 Files Investigational 57 Phase III Clinical Trial 57 eprodisate KIACTA TM 57 Expedited Review 57 Phase IIb Clinical Trial 57 Orphan Drug status 56 Contrave NDA 56 FDA Accepts 56 Not Approvable 56 Biologic License Application BLA 56 Drug Submission 56 Orphan Drug Status 56 Million Milestone Payment 56 MAA submission 56 Biologics License Application BLA 56 FIRAZYR 56 Ranolazine 56 Completes Patient Enrollment 56 Submits Response 56 OMP designation 56 Accelerated Approval 56 SILENOR 56 Novel Antibiotic 56 preclinical toxicology 56 supplemental Biologics License Application 56 Patient Enrollment 56 Fibrillex TM 56 Pivotal Phase III 56 Marketing Authorization 56 Receives Orphan Drug 55 Orphan Designation 55 Expanded Indication 55 Submits NDA 55 VALSTAR 55 Pivotal Clinical Trial 55 Premarket Approval PMA 55 Granted Orphan Drug 55 Saforis 55 PMA submission 55 European Medicines Evaluation 55 New Drug Application 55 inspectional observations 55 Marketing Authorisation 55 Tezampanel 55 Milestone Payment 55 Phase 2a Trial 55 FDA Approval 55 Phase IIb Trial 55 Positive Opinion 55 Silenor NDA 55 Orphan Drug designations 55 Marketing Approval PMA 55 proprietary Capillary Aerosolization Technology 55 Marketing Authorisation Application MAA 55 Drug Application 55 Risperidone Oral Solution 55 Barr ANDA 55 USFDA approval 55 IND Application 55 sNDA submission 55 resubmission 55 Testosterone Gel 55 Patent Covering 55 Cellegesic 55 FACTIVE R gemifloxacin 55 Phase IIa clinical trials 55 carcinogenicity studies 55 Receives Orphan Drug Designation 55 Submits Investigational 55 oxymorphone ER 55 corticotropin injection 55 alvimopan 54 Junovan 54 application sNDA 54 Receives Fast Track 54 elotuzumab 54 Investigational Agent 54 OMAPRO ™ 54 Investigational 54 Premarket Approval Application 54 granted Orphan Designation 54 Meets Primary Endpoint 54 balsalazide tablet 54 Submits Biologics License Application 54 Phase 2b Clinical Trial 54 amrubicin 54 NASDAQ Hearings Panel 54 Mylan Receives Approval 54 Receives Milestone Payment 54 Nasdaq Delisting Notification 54 Announces Tentative Approval 54 SILENOR TM 54 FDA Clearance 54 postoperative ileus POI 54 Levoleucovorin 54 Vilazodone 54 CIP TRAMADOL ER 54 L MTP PE 54 Application BLA 54 Biological License Application 54 Icatibant 54 Pegloticase 54 Milestone Payment From 54 Clinical Trial Data 54 NASDAQ Listing Qualification 54 BEMA Granisetron 54 interferon gamma 1b 54 investigational humanized monoclonal antibody 54 oral prodrug 54 granted Ortec 54 Androxal ® 54 Extina 54 BioDelivery Sciences 54 NDA submission 54 JAK Inhibitor 54 Civacir 54 Biologic License Application 54 QNEXA 54 novel trazodone formulation 54 mesylate tablets 54 Dyloject TM 54 APF# 53 Cethromycin 53 FOLOTYN ® 53 Nasdaq CYCC Nasdaq CYCCP 53 Receives Approvable Letter 53 Pulmonary Arterial Hypertension 53 MAb therapy 53 Phase 2a Clinical Trial 53 ZEGERID Capsules 53 Investigational Compound 53 Staff Deficiency Letter 53 Traficet EN 53 Xcytrin R 53 Shareholder Approval 53 Dacogen injection 53 Deficiency Letter 53 severe hypercholesterolemia 53 Metformin HCl 53 Romiplostim 53 Exelbine NDA 53 Linjeta TM 53 Demonstrates Significant 53 Generic Version 53 MyVax R 53 autologous cellular immunotherapy 53 Survival Benefit 53 Clinical Trial Results 53 Phase 2b Trial 53 CORLUX CORT # 53 Drug Candidate 53 Inhaled Insulin 53 Cimzia TM 53 liprotamase 53 Sanctura XR 53 GATTEX TM 53 Single Dose 53 Oral Calcitonin 53 Release Capsules 53 lucinactant 53 Keppra ® XR 53 approvability 53 Application MAA 53 NASDAQ Delisting Notice 53 Pivotal Phase 53 CINTREDEKIN BESUDOTOX 53 GRAS Status 53 Glatiramer Acetate 53 gabapentin enacarbil 53 Lenocta TM 53 Receives Positive Opinion 53 BYETTA ® 53 TELINTRA 53 Adjunctive Therapy 53 Regeneron Pharma 53 Zenvia ™ 53 balsalazide 53 pegloticase 53 pediatric exclusivity 53 Receives Complete Response 53 nonclinical studies 53 Epilepsy Drug 53 sNDAs 53 Friedreich Ataxia FRDA 53 FDA Anti Infective 53 BiovaxID TM 52 BRILINTA 52 Combination Treatment 52 MAGE A3 ASCI 52 Recombinant Human 52 OMNARIS Nasal Spray 52 assigned PDUFA 52 NASDAQ Deficiency Notice 52 Emezine 52 Schizophrenia Drug 52 Velaglucerase Alfa 52 liver resection surgeries 52 Investigational Treatment 52 IV acetaminophen 52 Scientific Advice 52 Milestone Payments 52 First Patient Enrolled 52 RNAi Therapeutics 52 Phase III Trials 52 Dose Escalation 52 alogliptin 52 ketolide antibiotic 52 Zingo TM 52 ATryn R 52 Hematological Malignancies 52 PREOS 52 EPCT 52 Phenoptin 52 Frova ® 52 LibiGel ® 52 ANDA submission 52 Valortim TM 52 Rhucin ® 52 prucalopride 52 trading symbol GCKO 52 Velac 52 Dose Ranging Study 52 markets HP Acthar 52 Orthopedic Advisory Panel 52 Presents Positive 52 Viviant 52 Pivotal Trial 52 PROMACTA 52 Present Preclinical Data 52 Archexin 52 Exelbine 52 Marketing Authorization Applications 52 Anturol TM 52 PNP inhibitor 52 Liver Toxicity 52 IMA# 52 PIX# trial 52 MethyPatch 52 Nabi HB Intravenous 52 Phase 1b Clinical Trial 52 Febuxostat 52 DATES Comments 52 TAXUS Element Stent System 52 Phase IIa Clinical Trial 52 Well Tolerated 52 Oracea TM 52 dasatinib Sprycel ® 52 Gout Drug 52 ORENCIA ® 52 Phase III Clinical Trials 52 Elagolix 52 Initiate Clinical Trial 52 Ambrisentan 52 Plicera 52 rasagiline tablets 52 PANVAC VF 52 HepaGam B 52 Paragraph IV certification 52 Telavancin 52 Satraplatin 52 Solzira TM 52 paliperidone palmitate 52 Premarket Approval 52 DPX Survivac 52 Entereg R 52 Tarceva TM 52 Metastatic Colorectal Cancer 52 Unsolicited Proposal 52 methylnaltrexone 52 Somatuline Depot 52 Kynapid 52 Submits Supplemental 52 Ustekinumab 52 Ranexa R 52 pseudobulbar affect PBA 52 TORISEL 52 Horizant 52 Azathioprine 52 Pruvel 52 ARIXTRA R 52 CHMP 52 Cholesterol Lowering Drug 52 bosutinib 51 Lilly Cymbalta 51 Evoltra TM 51 GRALISE 51 Omigard 51 ULTRASE 51 Investigational Drug 51 Alvesco R 51 ORENCIA R 51 NUEDEXTA ™ 51 Oxcarbazepine 51 Completes Enrollment 51 Ciclesonide 51 Luveniq 51 XP# XP# 51 NEBIDO 51 Kamada AAT 51 Lupus Drug 51 Regulatory Clearance 51 GLP toxicology studies 51 GMP Certification 51 BENLYSTA 51 AZILECT R 51 Ozarelix 51 Paragraph IV Certification 51 Prodarsan R 51 Orphan Medicinal Product 51 Extended Release Capsules 51 Rheumatoid Arthritis Patients 51 Files IND 51 RAPAFLO 51 efalizumab 51 Diabetic Nephropathy 51 Arimoclomol 51 Efficacy Results 51 Prestara TM 51 Orapred ODT 51 hoFH 51 REVLIMID lenalidomide 51 CONBRIZA 51 histamine dihydrochloride 51 Panzem R 51 Study Evaluating 51 Vfend 51 Product Designation 51 NYSE Amex PTN 51 Alogliptin 51 Torisel 51 Paragraph IV 51 MAXY alpha 51 Maribavir 51 adalimumab Humira 51 Bicifadine 51 Drug Eluting Stent System 51 oral cladribine 51 Aflibercept 51 Surfactant Technology 51 Phase IIa trial 51 R lenalidomide 51 Linjeta 51 Psoriasis Drug 51 Ampligen r 51 ANDA Filing 51 Sunesis Pharma 51 REG1 Anticoagulation System 51 Anti Infective Drugs 51 ANDA containing 51 cinacalcet HCl 51 TEMODAL 51 Trobalt 51 FACTIVE tablets 51 severe gastroparesis 51 Entereg alvimopan 51 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 51 Personalized Immunotherapy 51 FDA Advisory Panel 51 highly purified pasteurized 51 Pliaglis 51 Initiates Enrollment 51 PMA Supplement 51 OFIRMEV 51 Amlodipine Besylate 51 REVLIMID R 51 Protease Inhibitor 51 Krystexxa 51 novel histone deacetylase 51 Extended Release 51 vilazodone 51 Phase III Trial 51 HP Acthar Gel repository 51 Belimumab 51 Anti TNF 51 Aloxi Injection 51 MONOVISC 51 investigational antiplatelet agent 51 Migraine Drug 51 phase IIb trial 51 REMOXY NDA 51 Corlux 51 Ixempra 51 Versus Placebo 51 BYDUREON 51 KRN# 51 Financing Transactions 51 Listing Qualifications Staff 51 Immune Globulin Human 51 Improve Survival 51 Clinical Trials Update 51 faropenem medoxomil 51 UPLYSO 51 ONGLYZA ™ 51 Sprycel dasatinib 51 Paragraph IV Notice 51 NasdaqCM RPRX today 51 ARCOXIA 51 Nasdaq Deficiency Notice 51 Xenazine ® 51 Neupro R 51 Firazyr 51 Initiates Clinical 51 Uvidem 51 HoFH 51 postherpetic neuralgia PHN 51 Onrigin 51 Pirfenidone 51 Methylphenidate Transdermal System 51 Ophthalmic Drugs Advisory 51 KRYSTEXXA TM pegloticase 51 prGCD 51 commercialize oritavancin 51 TBC# 51 Successfully Completes Phase 51 Dapagliflozin 51 tacrolimus capsules 51 Regains NASDAQ 51 Nasdaq Notice Regarding 51 dextromethorphan quinidine 51 ENTEREG ® 51 PREOS R 51 AVASTIN 51 Soliris eculizumab 51 Zenvia Phase III 51 Audited Financials 51 Regulatory Approvals 51 Oracea R 51 rilonacept 51 sitaxsentan sodium 51 Desvenlafaxine Succinate 51 orphan medicinal product 51 Long Term Efficacy 51 Onsolis 51 tramiprosate ALZHEMED TM 51 SinuNase TM 51 Soriatane 51 Eszopiclone 51 NASDAQ BDSI 51 II Clinical Trial 51 Alair System 51 Actemra tocilizumab 51 sapropterin dihydrochloride 51 Exemption IDE approval 51 LymphoStat B TM 51 Raptiva R 51 Presents Preclinical Data 51 Somatuline R Autogel R 50 Clinical Trial Application 50 tiapamil 50 exocrine pancreatic insufficiency 50 EVIZON TM 50 ZOLINZA 50 eltrombopag 50 SPRYCEL ® 50 Pafuramidine 50 Sutent sunitinib 50 VIVITROL ® 50 Zenpep 50 Ticagrelor 50 Grants Orphan Drug 50 Initiates Clinical Trial 50 Prestara 50 TRANSDUR Bupivacaine 50 Pivotal Study 50 Nebido 50 IgG1 monoclonal antibody 50 mifamurtide 50 Nasdaq DVAX 50 AzaSite Plus 50 octreotide acetate 50 TSX SHQ 50 CHMP recommendation 50 Stavzor 50 Acetavance 50 Aerosurf 50 Allovectin 7 r 50 Arthritis Drug 50 LibiGel NDA 50 submitted Biologics License 50 Systemic Delivery 50 Medicinal Products EMEA 50 ATPace TM 50 Increlex R 50 Lung Cancer Drug 50 Initiates Phase III 50 testosterone gel LibiGel 50 vinorelbine emulsion 50 Entocort 50 ATL/TV# 50 RIGScan CR 50 NEBIDO R 50 Amlodipine Besylate Tablets 50 Palatin Technologies Inc. 50 Regulatory Approval 50 Ceplene histamine dihydrochloride 50 lomitapide 50 ELND# 50 CDP# 50 Prolongs Survival 50 Launches Generic Version 50 ezogabine 50 CHMP opinion 50 Receive Milestone Payment 50 Advanced Melanoma 50 Phase III Pivotal 50 PLAVIX ® 50 Oracea ® 50 pralatrexate injection folate analogue 50 Phase Ib study 50 Increlex TM 50 Exalgo TM 50 T Pred 50 Oncologic Drugs Advisory 50 Vernakalant 50 EvaMist TM 50 Demonstrates Sustained 50 Aurora Kinase 50 SPARLON 50 Going Concern Qualification 50 KRYSTEXXA TM 50 motexafin gadolinium Injection 50 Chemokine Receptor 50 Initiates Phase II 50 Unsolicited Proposal From 50 Zemiva TM 50 teduglutide 50 SYCREST 50 CLIA waiver 50 dalbavancin 50 Methylnaltrexone 50 VISICOL R 50 NASDAQ Listing 50 RAPTIVA 50 BiDil XR 50 Vimpat R 50 submitted supplemental Biologics 50 compound CIP FENOFIBRATE 50 #D#C# 50 dirucotide 50 Data Indicate 50 Phase IIb trials 50 virus HCV protease inhibitor 50 Achieves Primary Endpoint 50 Market Approval PMA 50 Known hypersensitivity 50 Doripenem 50 ZEVALIN ® 50 diabetic neuropathic pain 50 EPIX Pharmaceuticals 50 Boxed Warning 50 StaphVAX R 50 dihydrochloride Tablets 50 Cetrorelix 50 Troxatyl TM 50 Severe Sepsis 50 Phase IIB 50 Adentri 50 PLK1 SNALP 50 alogliptin NDA 50 Anturol ® 50 Colorectal Cancer Patients 50 investigational pan BCR 50 Aviptadil 50 HDAC Inhibitor 50 Horizant ™ 50 balsalazide disodium 50 ONSOLIS 50 Tesmilifene 50 PrevOnco 50 Flutiform ™ 50 RNAi Therapeutic 50 Nasdaq Delisting 50 Presents Preclinical 50 PROVIGIL 50 PRX # 50 ACUROX ® 50 Lorqess 50 include Phenoptin TM 50 raxibacumab 50 Inc. Nasdaq VVUS 50 mesylate tablets approved 50 pancreatic insufficiency 50 IV APAP 50 JAK2 Inhibitor 50 Earns Milestone Payment 50 Tasigna nilotinib 50 AMEX ONI 50 Diabetic Macular Edema 50 Improved Survival 50 Acute Attacks 50 BioGlue R 50 Investigational Oral 50 Hepatitis B Vaccine 50 ALVESCO R 50 pancreatic enzyme replacement 50 abatacept 50 ZEGERID Powder 50 inhaled formulation 50 Metabasis stockholders 50 Initiates Clinical Trials 50 Oracea 50 ANTEGREN 50 SILENOR ™ 50 Fungal Infections 50 Aliskiren 50 Demonstrates Positive 50 SPL# Gel vaginal microbicide 50 Surfaxin LS 50 PROMACTA ® 50 Preotact 50 Luveris 50 MKC# MKC# PP 50 CRTX 50 Genasense ® oblimersen 50 orBec 50 PDE4 inhibitor 50 Sumatriptan Succinate 50 talactoferrin 50 Nasdaq RPRX 50 Enzyme Replacement Therapy 50 ONGLYZA TM 50 GTC recombinant human 50 Rhucin ® recombinant 50 Unsolicited Tender Offer 50 Rhucin R 50 Final Approval 50 Dupuytren Contracture 50 ANDAs 50 FDA Oncologic Drugs 50 ACUROX 50 PEG SN# 50 iloperidone 50 Alzhemed TM 50 orBec R 50 pixantrone NDA 49 STELARA TM 49 Clofarabine 49 Tolvaptan 49 Dalbavancin 49 Ocrelizumab 49 FDA Approvals 49 PRISTIQ 49 NUVIGIL 49 Troxatyl 49 Antiviral Activity 49 Antidepressant Drug 49 HZT 49 orally administered inhibitor 49 Inhalation Solution 49 Rapaflo 49 Vitrasert R 49 Promacta 49 ruxolitinib 49 GALNS 49 Substantial Issuer Bid 49 human C1 inhibitor 49 Soliris TM eculizumab 49 Golimumab 49 CoFactor 49 miconazole Lauriad R 49 seliciclib CYC# 49 NOXAFIL 49 ATHX 49 Kuvan 49 BENLYSTA ® 49 Diabetic Patients 49 Protalix BioTherapeutics 49 Peginterferon alfa 2b 49 intravenous acetaminophen 49 anticancer compound 49 HCV protease inhibitor 49 naronapride 49 Cladribine 49 Ultracet R 49 Chemotherapy Regimen 49 PS# [001] 49 PRN FDA Approves 49 Previously Disclosed 49 Simvastatin Tablets 49 Zenvia TM 49 IL# PE#QQR 49 JANUVIA 49 Hycamtin 49 Acetavance TM 49 NEUMUNE 49 Zalbin 49 Reports Preclinical Data 49 Amigal 49 Confirmatory 49 Generic Versions 49 ocular formulation 49 Investigational Device Exemption IDE 49 please email chris@chfir.com 49 Small Molecule 49 successfully commercialize Iluvien 49 Zytiga 49 midstage trials 49 pemetrexed Alimta 49 Thelin TM 49 miconazole MBT 49 MEK Inhibitor 49 Triolex 49 Blood Pressure Drug 49 Drug Fails 49 JOULFERON 49 CHMP Opinion 49 apricitabine ATC 49 Angiox ® 49 Romidepsin 49 Morphine Sulfate 49 RANK Ligand inhibitor 49 R rilonacept Injection 49 ESTRASORB R 49 Aurexis 49 Tamibarotene 49 RAPTIVA R 49 VIBATIV 49 VitiGam 49 Roche Actemra 49 FY# Guidance 49 Low Doses 49 Testosterone MDTS ® 49 ATryn ® 49 Metabolic Disorder 49 Gel repository corticotropin injection 49 Rhucin 49 Demonstrates Potent 49 Factor VIIa 49 Fabry Disease 49 GTC recombinant form 49 Inhalation Powder 49 Rotarix R 49 RELISTOR ® 49 ABILIFY R 49 CERVARIX R 49 PEG INTRON 49 investigational atypical antipsychotic 49 bazedoxifene 49 Potent Antiviral Activity 49 Drug Applications ANDAs 49 Cintredekin besudotox 49 ANDA 49 ViRexx Announces 49 targeted radiotherapeutic 49 NexMed Receives 49 AMEX IVX LSE IVX.L 49 refractory chronic lymphocytic 49 ALN PCS 49 Protexia R 49 No Objection Letter 49 XOMA 3AB 49 NASDAQ Delisting 49 self affirmed GRAS 49 Bazedoxifene 49 Delayed Release 49 Vion Pharmaceuticals 49 BAL# [002] 49 Zensana 49 APTIVUS ritonavir 49 Noxafil 49 cell lymphoma CTCL 49 oritavancin 49 POSIDUR TM 49 TWYNSTA ® 49 Glybera R 49 Fixed Dose Combination 49 bifeprunox 49 StaphVAX 49 Cinryze ™ 49 TRISENOX ® 49 SmPC 49 oral nucleoside analogue 49 Ampligen R 49 proteasome inhibitor 49 ZEFTERA ™ 49 IDE Investigational Device Exemption 49 Exalgo 49 BioGlue ® 49 COLAZAL R 49 Hsp# Inhibitor 49 Preclinical Data 49 Faropenem 49 post menopausal osteoporosis 49 Silenor ® doxepin 49 Receptor Agonist 49 Voluntary Withdrawal 49 Ecallantide 49 Cutaneous T 49 Hedgehog Pathway Inhibitor 49 Staff Determination 49 VIVUS Announces 49 Cinacalcet HCl 49 Q#IR 49 Topiramate Tablets 49 Transcept Pharmaceuticals 49 See CLINICAL PHARMACOLOGY 49 Phase IIa trials 49 ZADAXIN ® 49 ATPace 49 Inhalation Aerosol 49 vapreotide acetate 49 PROVENGE ® 49 Evoltra 49 Cladribine Tablets 49 palifosfamide 49 heterozygous FH 49 NASDAQ AVNR 49 DOR BioPharma Announces 49 Pralatrexate 49 Patients Treated With 49 TRX1 49 UCB Cimzia 49 confirmatory Phase 3 49 Generic Lovenox 49 pulls Darvon painkiller 49 Announces Poster Presentations 49 NASDAQ SHPGY 49 Hepatotoxicity 49 Fanapt ™ 49 methylnaltrexone bromide 49 Esbriet ® 49 SUPPRELIN R LA 49 GLASSIA 49 non nucleoside HCV 49 Nasdaq Listing Requirements 49 Aryplase 49 Cimzia ® 49 SCHWARZ PHARMA 49 TachoSil 49 Initiate Phase 49 NYSE Amex Listing 49 Pharmacokinetic Study 49 Combination Therapy 49 Clinical Trial Evaluating 49 Ramelteon 49 Raptiva ® 49 Nasdaq HALO 49 THELIN 49 OMNARIS HFA 49 Bupropion HCl ER 49 Phase 2b Study 49 LIALDA 49 Inc. NASDAQ HITK 49 BEMA TM LA 49 Begins Dosing 49 Telaprevir 49 developing ostarine selective 49 AMITIZA R 49 Onco TCS 49 IIa trial 49 Upcoming Milestones 49 Aztreonam Lysine 49 nanofiltered plasma derived 49 Ceflatonin 49 ecallantide 49 IPLEX 49 investigational compound 49 Recent Accomplishments 49 LE SN# 49 Topotecan 49 proprietary transdermal patch 49 Liprotamase 49 FDA APPROVES 49 Centralized Procedure 49 AstraZeneca Symbicort 49 Drug Coated Stent 49 Zelrix 49 Cinryze TM 49 ACOMPLIA R 49 Adjuvant Chemotherapy 49 TRISENOX R 49 GRAS determination 49 AAG geldanamycin analog 49 Cefprozil 49 Iloperidone 49 Octreotide 49 CERVARIX 49 registrational trial 49 k premarket 49 Adalimumab 49 Ampligen 49 NASDAQ PGNX 49 vaginal lidocaine 49 Prodarsan 49 etanercept Enbrel 49 TYZEKA 49 RoACTEMRA 49 Gamunex C 49 Combidex 49 Exocrine Pancreatic Insufficiency 49 Proxy Proposals 49 ALLOS THERAPEUTICS 48 Voraxaze 48 lubiprostone 48 E1 INT TM 48 PROCHIEVE 48 Weight Loss Drug 48 Amrubicin 48 Solzira 48 Egrifta 48 Stedesa 48 subsidiaries visit http:/www.apricusbio.com 48 Tracleer R 48 Kiacta 48 Taxotere ® 48 Wellbutrin XL R 48 Receives Notification 48 Oral Suspension #mg 48 SEASONALE R 48 REMICADE ® 48 FUSILEV ® 48 formerly LymphoStat B 48 CRMD# 48 cutaneous T 48 Anti Tumor 48 Initiates Phase 2b 48 Potential Delisting 48 Kuvan TM sapropterin 48 Dyloject 48 generation NNRTI 48 Abbreviated New 48 Release Tablets 48 EGRIFTA ™ 48 Avanafil 48 Saxagliptin 48 Daytrana ® 48 Naglazyme 48 Unresectable 48 Improves Survival 48 Anidulafungin 48 Listing Compliance 48 casopitant 48 Shigamabs ® 48 Demonstrates Efficacy 48 Safinamide 48 ALN TTR 48 PSN# [002] 48 Itraconazole 48 ELIQUIS 48 Low Dose 48 Teflaro 48 Motavizumab 48 Orphan Drug